Evidence map›Paper›PMID 31865463›Full record

ReviewJournal of gastroenterology2020

Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review.

Toshio Watanabe, Yasuhiro Fujiwara, Francis K L Chan

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 127 citations in OpenAlex.

  1. Trial
  2. From pain relief to mucosal grief: A comprehensive review of NSAID enteropathy.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Potential of Alkaloids fromCurrent issues in molecular biology · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Diaphragm disease-When non-steroidal anti-inflammatory drugs bit the small bowel.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025
    Article
  20. Frontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Toshio WatanabeDepartment of Gastroenterology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. watanabet@med.osaka-cu.ac.jp.ORCID http://orcid.org/0000-0002-8567-0585
Yasuhiro FujiwaraDepartment of Gastroenterology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
Francis K L ChanDepartment of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China.
Osaka City University · JPChinese University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in small-bowel endoscopy such as capsule endoscopy have shown that non-steroidal anti-inflammatory drugs (NSAIDs) frequently damage the small intestine, with the prevalence rate of mucosal breaks of around 50% in chronic users. A significant proportion of patients with NSAIDs-induced enteropathy are asymptomatic, but some patients develop symptomatic or complicated ulcers that need therapeutic intervention. Both inhibition of prostaglandins due to the inhibition of cyclooxygenases and mitochondrial dysfunction secondary to the topical effect of NSAIDs play a crucial role in the early process of injury. As a result, the intestinal barrier function is impaired, which allows enterobacteria to invade the mucosa. Gram-negative bacteria and endogenous molecules coordinate to trigger inflammatory cascades via Toll-like receptor 4 to induce excessive expression of cytokines such as tumor necrosis factor-α and to activate NLRP3 inflammasome, a multiprotein complex that processes pro-interleukin-1β into its mature form. Finally, neutrophils accumulate in the mucosa, resulting in intestinal ulceration. Currently, misoprostol is the only drug that has a proven beneficial effect on bleeding small intestinal ulcers induced by NSAIDs or low-dose aspirin, but its protection is insufficient. Therefore, the efficacy of the combination of misoprostol with other drugs, especially those targeting the innate immune system, should be assessed in the next step.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsAspirinCapsule EndoscopyGastrointestinal HemorrhageHumansIntestinal DiseasesIntestine, SmallMisoprostolPeptic UlcerAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsAspirinMisoprostolEnteropathyInnate immunityLow-dose aspirinMisoprostolNon-steroidal anti-inflammatory drug

Identifiers

PMID31865463
PMCPMC7188723
OpenAlexW2994847826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.